Paradigm Change Coming in Secondary Stroke Prevention: OCEANIC-STROKE (2026)
Paradigm Change Coming in Secondary Stroke Prevention: OCEANIC-STROKE (2026)
Source: Medscape -April 15, 2026(The trial presented at AHA 2026 and published in NEJM, confirming their high scientific impact beyond Medscape).
• New class: Factor XIa inhibitor (Asundexian)
• Aim: reduce stroke risk with less bleeding than traditional anticoagulants
Background
• Aspirin → ~15% risk reduction
• Anticoagulants (AF) → 60–70% reduction but ↑ bleeding
Need: safer antithrombotic option
Study Design
• ~6150 patients
• Non-cardioembolic stroke or high-risk TIA
• On top of:
* Aspirin ± clopidogrel
• Compared:
* Asundexian 50 mg daily vs placebo
Key Results
• ↓ Ischemic stroke risk by 25% , ↓ composite CV outcomes
• Benefit consistent across subgroups
Safety
• No increase in major bleeding (ISTH)
• Similar bleeding vs placebo
Clinical Insight
👉 First major advance beyond aspirin in ~50 years
👉 Effective in atherosclerotic stroke (non-cardioembolic)
❗ Not effective in AF (different mechanism)
🎯 Take-home
Asundexian adds benefit on top of standard antiplatelet therapy without increasing bleeding
